Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging safety and pharmacokinetic study of PI-2301 in secondary progressive multiple sclerosis
2007-007759-15Phase 2Completed
- Sponsor
- Peptimmune
- Start
- Aug 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of plovamer acetate in secondary-progressive multiple sclerosis (SPMS), sponsored by Peptimmune. Primary endpoint: Safety parameters. Started Aug 2008; status: completed.
02
Drugs
plovamer acetate
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2007-007759-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007759-15.